口服司美格鲁肽对赖诺普利、华法林、地高辛和二甲双胍药代动力学的影响
两项单序列交叉试验在健康受试者中评估口服司美格鲁肽及SNAC对赖诺普利、华法林、地高辛和二甲双胍药代动力学的影响。结果显示口服司美格鲁肽对赖诺普利、华法林和地高辛的AUC和Cmax无明显影响,但使二甲双胍AUC增加32%(90%CI 1.23-1.43),Cmax不受影响;基于二甲双胍宽治疗指数,该暴露增加被认为无临床相关性。
要点
- 口服司美格鲁肽不影响赖诺普利、华法林、地高辛的AUC和Cmax。
- 口服司美格鲁肽使二甲双胍AUC增加32%(90%CI 1.23-1.43),Cmax不变。
- SNAC单用不影响上述四种药物的暴露,二甲双胍暴露增加无临床相关性。
核心结论
- 口服司美格鲁肽或SNAC单用似乎不影响赖诺普利、华法林或地高辛的暴露。
- 口服司美格鲁肽使二甲双胍AUC增加32%(90%CI 1.23-1.43),基于其宽治疗指数认为无临床相关性。
研究设计与样本
- 两项单序列交叉试验在健康受试者中评估口服司美格鲁肽及SNAC对四种药物药代动力学的影响。
- 试验1纳入52名健康受试者,试验2纳入32名健康受试者。
主要发现
- 口服司美格鲁肽对赖诺普利、华法林和地高辛的AUC和Cmax无明显影响。
- 口服司美格鲁肽使二甲双胍AUC增加32%(90%CI 1.23-1.43),Cmax不受影响。
- SNAC单用不影响赖诺普利、华法林、地高辛或二甲双胍的暴露。
- 不良事件与既往GLP-1受体激动剂观察结果一致。
临床怎么用
- 口服司美格鲁肽与赖诺普利、华法林或地高辛合用时无需调整剂量。
- 口服司美格鲁肽与二甲双胍合用时,基于二甲双胍宽治疗指数,暴露增加无临床相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral semaglutide is a tablet co-formulation of the human glucagon-like peptide-1 (GLP-1) analog semaglutide with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The absorption of coadministered oral drugs may be altered due to enhancement by SNAC, potential gastric emptying delay by semaglutide, or other mechanisms. Two one-sequence crossover trials investigated the effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin. METHODS: In trial 1, 52 healthy subjects received lisinopril (20 mg single dose) or warfarin (25 mg single dose) with subsequent coadministration with SNAC alone (300 mg single dose), followed by oral semaglutide 20 mg once daily (steady state). In trial 2, 32 healthy subjects received digoxin (500 μg single dose) or metformin (850 mg twice daily for 4 days), with subsequent coadministration with SNAC alone followed by oral semaglutide, as in trial 1. RESULTS: There were no apparent effects of oral semaglutide on area under the plasma concentration-time curve (AUC) and maximum plasma concentration (Cmax) for lisinopril, warfarin, and digoxin. The AUC of metformin was increased by 32% (90% confidence interval 1.23-1.43) by oral semaglutide coadministration versus metformin alone, whereas the Cmax was unaffected. SNAC alone did not affect exposure of lisinopril, warfarin, digoxin, or metformin. Adverse events were in line with those previously observed for GLP-1 receptor agonists. CONCLUSIONS: Oral semaglutide or SNAC alone did not appear to affect the exposure of lisinopril, warfarin, or digoxin, and, based on its wide therapeutic index, the higher metformin exposure with oral semaglutide was not considered clinically relevant.
引用
- Bækdal TA, Borregaard J, Hansen CW, et al. Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects. Clin Pharmacokinet. 2019. PMID: 30945118. doi:10.1007/s40262-019-00756-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。